质子治疗H&N/CNS恶性肿瘤后有严重听力损害风险的儿科患者

IF 7.4 1区 医学 Q1 ONCOLOGY International Journal of Radiation Oncology Biology Physics Pub Date : 2025-03-01 Epub Date: 2025-02-03 DOI:10.1016/j.ijrobp.2024.11.016
E. Hwang , S. Gaito , D. Thwaites , V. Ahern , E. Smith , G. Whitfield , P. Sitch , A. France , M. Aznar
{"title":"质子治疗H&N/CNS恶性肿瘤后有严重听力损害风险的儿科患者","authors":"E. Hwang ,&nbsp;S. Gaito ,&nbsp;D. Thwaites ,&nbsp;V. Ahern ,&nbsp;E. Smith ,&nbsp;G. Whitfield ,&nbsp;P. Sitch ,&nbsp;A. France ,&nbsp;M. Aznar","doi":"10.1016/j.ijrobp.2024.11.016","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Recent work by the Pediatric Normal Tissue Effects in the Clinic (PENTEC) hearing loss task force provides guidance on benchmark dose constraints to reduce hearing loss but does not generate individualised risk estimations for patients. Uniquely, a risk calculation model was presented in 2021 by Keilty et al. for determining the likelihood of severe hearing impairment (HI) for paediatric patients treated with photon radiation therapy. This study aimed to validate their risk-prediction model for our paediatric patient cohort treated with proton therapy (PT) for malignancies of the head and neck (H&amp;N) or central nervous system (CNS).</div></div><div><h3>Methods</h3><div>This was a single-institution study which extracted data on all patients aged ≤ 18 years treated with PT between Feb 2010 – Feb 2022 for malignancies of the H&amp;N/CNS, either via the UK Proton Overseas Programme or at The Christie PT centre. The factors required for input into the Keilty model were extracted: age at PT, time since end of PT, mean cochlea dose, and platinum chemotherapy doses. Validation was performed using the statistical software R v 4.3.1, which analysed event discrimination and model calibration.</div></div><div><h3>Results</h3><div>587 patients met inclusion criteria. Validation of the model demonstrated excellent discriminative ability, with an “optimal” cut-off value of 16% at a specificity and sensitivity of 82%. However, model calibration was less satisfactory, indicating an overestimation of risk of severe HI by the model as compared to clinically observed events in our cohort, possibly linked to differences in event scoring between the model developers and this study, and short follow-up time in this study.</div></div><div><h3>Conclusion</h3><div>The published (photon-based) model of Keilty et al. was validated in a PT context, demonstrating a high discriminative ability to determine patients at high risk versus low risk for severe HI. However the overall observed risk was lower than model predictions.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Page e3"},"PeriodicalIF":7.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identifying Pediatric Patients at Risk of Severe Hearing Impairment After Treatment for Malignancies of the H&N/CNS with Proton Therapy\",\"authors\":\"E. Hwang ,&nbsp;S. Gaito ,&nbsp;D. Thwaites ,&nbsp;V. Ahern ,&nbsp;E. Smith ,&nbsp;G. Whitfield ,&nbsp;P. Sitch ,&nbsp;A. France ,&nbsp;M. Aznar\",\"doi\":\"10.1016/j.ijrobp.2024.11.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>Recent work by the Pediatric Normal Tissue Effects in the Clinic (PENTEC) hearing loss task force provides guidance on benchmark dose constraints to reduce hearing loss but does not generate individualised risk estimations for patients. Uniquely, a risk calculation model was presented in 2021 by Keilty et al. for determining the likelihood of severe hearing impairment (HI) for paediatric patients treated with photon radiation therapy. This study aimed to validate their risk-prediction model for our paediatric patient cohort treated with proton therapy (PT) for malignancies of the head and neck (H&amp;N) or central nervous system (CNS).</div></div><div><h3>Methods</h3><div>This was a single-institution study which extracted data on all patients aged ≤ 18 years treated with PT between Feb 2010 – Feb 2022 for malignancies of the H&amp;N/CNS, either via the UK Proton Overseas Programme or at The Christie PT centre. The factors required for input into the Keilty model were extracted: age at PT, time since end of PT, mean cochlea dose, and platinum chemotherapy doses. Validation was performed using the statistical software R v 4.3.1, which analysed event discrimination and model calibration.</div></div><div><h3>Results</h3><div>587 patients met inclusion criteria. Validation of the model demonstrated excellent discriminative ability, with an “optimal” cut-off value of 16% at a specificity and sensitivity of 82%. However, model calibration was less satisfactory, indicating an overestimation of risk of severe HI by the model as compared to clinically observed events in our cohort, possibly linked to differences in event scoring between the model developers and this study, and short follow-up time in this study.</div></div><div><h3>Conclusion</h3><div>The published (photon-based) model of Keilty et al. was validated in a PT context, demonstrating a high discriminative ability to determine patients at high risk versus low risk for severe HI. However the overall observed risk was lower than model predictions.</div></div>\",\"PeriodicalId\":14215,\"journal\":{\"name\":\"International Journal of Radiation Oncology Biology Physics\",\"volume\":\"121 3\",\"pages\":\"Page e3\"},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology Biology Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0360301624035909\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624035909","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:儿童临床正常组织效应(PENTEC)听力损失工作组最近的工作提供了基准剂量限制的指导,以减少听力损失,但没有为患者产生个性化的风险估计。独特的是,Keilty等人在2021年提出了一个风险计算模型,用于确定接受光子放射治疗的儿科患者发生严重听力障碍(HI)的可能性。本研究旨在验证他们的风险预测模型,用于我们接受质子治疗(PT)治疗头颈部(H&;N)或中枢神经系统(CNS)恶性肿瘤的儿科患者队列。方法:这是一项单机构研究,提取了2010年2月至2022年2月期间通过英国质子海外项目或克里斯蒂PT中心接受h&n /CNS恶性肿瘤PT治疗的所有年龄≤18岁患者的数据。提取需要输入Keilty模型的因素:PT时的年龄、PT结束后的时间、平均耳蜗剂量和铂化疗剂量。使用统计软件R v 4.3.1进行验证,分析事件判别和模型校准。结果587例患者符合纳入标准。模型的验证显示出出色的判别能力,“最佳”临界值为16%,特异性和敏感性为82%。然而,模型校准不太令人满意,表明与我们队列中临床观察到的事件相比,该模型高估了严重HI的风险,这可能与模型开发者和本研究之间事件评分的差异以及本研究的随访时间短有关。Keilty等人发表的(基于光子的)模型在PT背景下得到了验证,显示出高度判别能力,可以确定严重HI的高风险患者和低风险患者。然而,观察到的总体风险低于模型预测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Identifying Pediatric Patients at Risk of Severe Hearing Impairment After Treatment for Malignancies of the H&N/CNS with Proton Therapy

Objectives

Recent work by the Pediatric Normal Tissue Effects in the Clinic (PENTEC) hearing loss task force provides guidance on benchmark dose constraints to reduce hearing loss but does not generate individualised risk estimations for patients. Uniquely, a risk calculation model was presented in 2021 by Keilty et al. for determining the likelihood of severe hearing impairment (HI) for paediatric patients treated with photon radiation therapy. This study aimed to validate their risk-prediction model for our paediatric patient cohort treated with proton therapy (PT) for malignancies of the head and neck (H&N) or central nervous system (CNS).

Methods

This was a single-institution study which extracted data on all patients aged ≤ 18 years treated with PT between Feb 2010 – Feb 2022 for malignancies of the H&N/CNS, either via the UK Proton Overseas Programme or at The Christie PT centre. The factors required for input into the Keilty model were extracted: age at PT, time since end of PT, mean cochlea dose, and platinum chemotherapy doses. Validation was performed using the statistical software R v 4.3.1, which analysed event discrimination and model calibration.

Results

587 patients met inclusion criteria. Validation of the model demonstrated excellent discriminative ability, with an “optimal” cut-off value of 16% at a specificity and sensitivity of 82%. However, model calibration was less satisfactory, indicating an overestimation of risk of severe HI by the model as compared to clinically observed events in our cohort, possibly linked to differences in event scoring between the model developers and this study, and short follow-up time in this study.

Conclusion

The published (photon-based) model of Keilty et al. was validated in a PT context, demonstrating a high discriminative ability to determine patients at high risk versus low risk for severe HI. However the overall observed risk was lower than model predictions.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
期刊最新文献
The Critical Role of Dose Homogeneity in Modern Breast Hypofractionation Radiation Dose and Lymphedema Risk After Immediate Lymphatic Reconstruction and Axillary Lymph Node Dissection Geographic and Sociodemographic Disparities in Access to Radiation Therapy in Brazil: A Nationwide Cross-Sectional Study (2017-2022) In Reply to Acharya Cancer as a Chronic Disease and the Role of Reirradiation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1